Detailed insight into the pathophysiology and the behavioral complications associated with the Parkinson's disease and its medications
Authors:
Open Access
- 15 June 2022
- journal article
- review article
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 8 (1) , 1-14
Abstract
Background: The loss of dopamine neurons in the substantia nigra, as well as other mostly catecholaminergic neurons, causes many of the motor symptoms that define Parkinson's disease. Parkinson's disease is commonly thought of as a movement disorder, the significant prevalence of psychiatric complications such as cognitive impairment, and psychosis suggests it should be considered a neuropsychiatric illness, and all behavioral complications are linked to growing disability and the medication.Main body: Apart from the disease-induced abnormalities, there are several other side effects of the disease and also from the medication used to prevent the disease. This article focuses on the pathogenesis of Parkinson’s disease and also the behavioral abnormalities caused by the disease and its medication. The study's data were gathered by searching several review articles and research papers from a variety of sources, including Elsevier, PubMed, Research Gate, Journal of Pharmaceutical Science, etc., from the year 1985 to 2021. Parkinson's disease is a neurodegenerative disease caused by a variety of complex processes. It is responsible not just for motor symptoms, but also for a variety of behavioral symptoms that can arise as a result of the disease and/or medication.Conclusion: Only symptomatic drugs are available; thus, finding treatments that directly address the disease mechanisms causing Parkinson’s disease is essential. To alleviate the disease's burden on patients and their families, better treatments for the neuropsychiatric repercussions of Parkinson's disease are required.GraphicalKeywords
This publication has 106 references indexed in Scilit:
- LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1Human Molecular Genetics, 2012
- The homocysteine-inducible endoplasmic reticulum (ER) stress protein Herp counteracts mutant α-synuclein-induced ER stress via the homeostatic regulation of ER-resident calcium release channel proteinsHuman Molecular Genetics, 2011
- Neuroprotective strategies involving ROS in Alzheimer diseaseFree Radical Biology and Medicine, 2011
- LRRK2 Mutant iPSC-Derived DA Neurons Demonstrate Increased Susceptibility to Oxidative StressCell Stem Cell, 2011
- Caffeine protects against MPTP‐induced blood‐brain barrier dysfunction in mouse striatumJournal of Neurochemistry, 2008
- Mitochondrial dysfunction and oxidative stress in neurodegenerative diseasesNature, 2006
- Dopamine covalently modifies and functionally inactivates parkinNature Medicine, 2005
- DJ‐1 has a role in antioxidative stress to prevent cell deathEMBO Reports, 2004
- α-Synuclein Locus Triplication Causes Parkinson's DiseaseScience, 2003
- α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodiesProceedings of the National Academy of Sciences, 1998